Restless Legs Syndrome: A General Overview — Criteria, Causes, and Treatment

Restless legs syndrome (RLS, also known as Willis-Ekbom disease) is often dismissed as subjective pre-sleep "nervousness," yet it is a well-defined neurological disorder with established diagnostic criteria. Current epidemiological data put the prevalence of RLS in the general adult population at anywhere from a few to more than a dozen percent, depending on study methodology, with a clearly higher frequency in women than men and rates that rise with age.

The International Restless Legs Syndrome Study Group (IRLSSG) developed and regularly updates the diagnostic criteria for RLS, which — unlike many subjective complaints — require the simultaneous fulfillment of several specific features, not just a general sense of "restlessness in the legs."

This fifth criterion — excluding other causes (so-called RLS mimics) — has significant practical importance, since nocturnal leg cramps, painful legs and moving toes syndrome, venous edema, or peripheral neuropathy can themselves produce similar, though not identical, leg complaints, and a mistaken diagnosis of RLS leads to inappropriate treatment.

RLS is divided into a primary (idiopathic) form, usually with an earlier onset, often with a family history and a chronic, slowly progressive course, and a secondary form, resulting from another, identified disease or condition — where treating the underlying cause can be a key element of therapy, not just an addition to symptomatic treatment.

In dialysis patients with kidney failure, management includes limiting medications that can worsen symptoms (e.g., certain antidepressants or dopamine antagonists), correcting anemia with erythropoietin and iron, and, when needed, dopaminergic treatment — symptoms of uremic RLS typically, though not immediately, resolve after a successful kidney transplant, which itself confirms the secondary rather than merely coincidental nature of this form.

Although RLS and Parkinson's disease are entirely different conditions with different courses and prognoses, both involve dysfunction of the dopaminergic system, which explains why some drugs originally used for Parkinson's are also used in RLS. Unlike Parkinson's disease, RLS does not involve massive loss of dopaminergic neurons — the problem is instead a subtler dysregulation of dopamine transmission, likely linked to iron metabolism in the brain, which is an essential cofactor in dopamine synthesis.

This link between iron and dopamine explains why iron deficiency — even without full-blown anemia — is so strongly associated with RLS, and why assessing iron stores (including ferritin levels, not just a blood count) is a standard part of the workup for every newly diagnosed RLS case, regardless of whether the primary or secondary form is suspected.

Dopamine receptor agonists — pramipexole and ropinirole — are effective drugs for relieving moderate to severe RLS symptoms and were, for years, treated as first-line therapy. The two drugs have similar efficacy in reducing RLS symptoms and involuntary limb movements during sleep, with no significant differences between them in comparative trials.

Alpha-2-delta ligands (gabapentin, pregabalin, gabapentin enacarbil) are today, alongside correcting iron deficiency, an important first-line alternative in many guidelines, especially for patients with a milder course, coexisting neuropathic pain or anxiety disorders, and those for whom dopaminergic treatment would carry a high augmentation risk given an expected long duration of therapy. In patients with confirmed iron deficiency (low ferritin, even with a normal blood count), iron supplementation — oral or, in select cases, intravenous — can be an effective causal, not merely symptomatic, intervention.

Non-pharmacological elements of management include avoiding caffeine, alcohol, and nicotine in the evening, regular, moderate physical activity during the day (though intense exercise right before bed can paradoxically worsen symptoms in some patients), and reviewing current medications for those that can worsen RLS — which for some patients reduces symptom severity without adding further pharmacotherapy.

Because RLS symptoms typically worsen in the evening and at rest, the condition directly interferes with falling asleep, and many patients also experience periodic limb movements during sleep (PLMS), which — even without the patient fully waking up or being aware of it — fragment sleep architecture and contribute to chronic daytime fatigue. Chronic, untreated RLS is associated with an increased risk of insomnia, lowered mood, and a reduction in quality of life comparable to other chronic conditions that affect daily functioning.

Restless legs syndrome is a good example of a condition where an accurate diagnosis — based on specific, verifiable criteria rather than a general impression of "restless legs" — directly translates into appropriate treatment. Distinguishing the primary from the secondary form, systematically assessing iron stores, and being aware of the augmentation risk with dopaminergic treatment are the elements that set well-managed RLS care apart from purely symptomatic treatment.